Trump administration authorises 172 million barrel SPR drawdown as 32 IEA nations coordinate record emergency oil release
Read More 5 minute read Pharma Industry News Takeda’s oveporexton Phase 3 trials show broad success in narcolepsy type 1, paving way for 2025 FDA submission Takeda announces pivotal Phase 3 trial results for oveporexton (TAK-861), showing statistically significant improvements in narcolepsy type 1 symptoms. Regulatory filings planned. byPallavi MadhirajuJuly 14, 2025